Cinpanemab
| Monoclonal antibody | |
|---|---|
| Type | ? |
| Target | α-Synuclein |
| Clinical data | |
| Other names | BIIB054; BIIB-054; NI-202; NI202 |
| Identifiers | |
| CAS Number | |
| DrugBank | |
| UNII | |
Cinpanemab (INN, USAN; developmental code names BIIB054, NI-202) is an anti-α-synuclein drug acting as a monoclonal antibody against α-synuclein which was under development for the treatment of Parkinson's disease.[1][2] It showed no significant influence on disease progression in a 52-week phase 2 clinical trial.[2] The drug reached phase 2 clinical trials but was discontinued in 2021 due its lack of effectiveness.[1][3][2] It was under development by Biogen.[1]
See also
[edit]References
[edit]- ^ a b c "Cinpanemab". AdisInsight. Springer Nature Switzerland AG. 4 June 2021. Retrieved 26 September 2024.
- ^ a b c Baggett D, Olson A, Parmar MS (2024). "Novel Approaches Targeting in α-Synuclein for Parkinson's Disease: Current Progress and Future Directions for the Disease-Modifying Therapies". Brain Disorders. 16. Elsevier BV: 100163. doi:10.1016/j.dscb.2024.100163. ISSN 2666-4593.
- ^ Lang AE, Siderowf AD, Macklin EA, Poewe W, Brooks DJ, Fernandez HH, et al. (August 2022). "Trial of Cinpanemab in Early Parkinson's Disease". N Engl J Med. 387 (5): 408–420. doi:10.1056/NEJMoa2203395. PMID 35921450.